人血丙种球蛋白治疗小儿难治性肺炎支原体肺炎的临床观察

目的:探讨人血丙种球蛋白治疗难治性肺炎支原体肺炎(RMPP)的临床疗效及对其体液免疫的影响。方法:将90例难治性肺炎支原体肺炎患儿随机分成治疗组和对照组各45例,两组患儿入院后均行体液免疫检测等实验室检查,两组患儿均给予抗感染、止咳化痰、吸氧、镇静、雾化吸入等常规治疗,治疗组在常规治疗的基础上加用人血丙种球蛋白治疗,记录两组治疗前后临床症状、体征、胸部X线片情况及体液免疫的改变。结果:治疗组临床症状改善或体征消失、好转时间、平均住院时间明显短于对照组(P<0.01);治疗组IgG水平较治疗前相比明显升高,差异有统计学意义(P<0.05)。结论:应用人血丙种球蛋白可调节难治性肺炎支原体肺炎患儿的免疫功能,疗效显著,缩短住院时间。

Objective: To investigate the clinical efficacy of blood gamma globulin treatment of refractory mycoplasma pneumoniae pneumonia and its humoral immune.Methods: 90 patients with refractory mycoplasma pneumonia were randomly divided into treatment group and control group,45 cases each group.Humoral immunity testing and other laboratory tests were implement to both groups of children.The two groups of patients were given antibiotics,cough and phlegm,oxygen,sedation,aerosol inhalation and other conventional treatment.Treatment group on the basis of the conventional treatment plus human blood gamma globulintreatment.Changes in clinical symptoms and signs,chest X-ray situation and humoral immunity were recorded before and after treatment.Result: The time of improvement of clinical symptoms and signs as well as the average hospital stay in the treatment group were all significantly shorter than the control group.IgG levels of the treatment group compared to before treatment was significantly increased,the difference was statistically significant.Conclusions: Human serum gamma globulin may regulate the immune function of the refractory mycoplasma pneumonia and shorter hospital stays significantly and worthy of promotion and application.